The study findings, taken in conjunction with the known myocardial abnormalities of fibrosis and conduction-system degeneration, make it probable that acute unstable arrhythmias were responsible for the majority of sudden deaths. The study was a multicenter investigation, and the ability to request autopsies was limited.
We agree that progressive skeletal-muscle weakness leading to respiratory failure is a significant issue in the care of patients with myotonic dystrophy. Respiratory failure was the most common cause of death in our study. Whether respiratory status had a role in the initiation of the event leading to sudden death is not clear. As detailed in our article, the presence of severe muscular weakness did affect the patients' and caregivers' decisions regarding the treatment of unstable arrhythmias. On the basis of our study findings, we agree that a yearly noninvasive evaluation, including assessment for atrial tachyarrhythmias and severe conduction abnormalities on the ECG, will aid in determining the risk of sudden death. We do not agree that nonmortality outcomes from nonrandomized observations in a referred population have proved the diagnostic usefulness of invasive electrophysiological studies or the therapeutic benefit of prophylactic pacemakers in the management of sudden death in patients with myotonic dystrophy. [1] [2] [3] The cohort analysis by Hermans and colleagues provides support for our finding that sudden death is a common cause of death among patients with myotonic dystrophy type 1 and that pacemakers may not prevent sudden death. We understand the rationale behind their recommendation for prophylactic ICDs. However, we believe that the population of patients with myotonic dystrophy type 1 is of sufficient size and clinical complexity that a prospective mortality assessment of the benefit of ICDs is indicated. With the worldwide interest in evaluating methods to prevent sudden death in patients with myotonic dystrophy type 1, a multinational trial would be optimal. We encourage investigators providing care for patients with myotonic dystrophy type 1 to design and implement such a necessary trial.
Vrtovec and Haddad question whether QT prolongation detected on ECG predicts sudden death in patients with myotonic dystrophy type 1. We found no independent association between markers of prolonged repolarization and sudden death.
Sovari and Dudley hypothesize that TGF-β1 could serve as a biomarker for sudden death in patients with myotonic dystrophy type 1. We did not evaluate TGF-β1 and have seen no published data. 
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Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study. evidence that Merkel-cell carcinoma is not smallcell lung cancer, and as we learn more about Merkel-cell carcinoma and its molecular fingerprints, it may well turn out to be a distinct entity. However, we contend that there are more than enough similarities (histologic appearance, metastatic incidence, pattern of spread, and sensitivity to radiation and chemotherapy) to warrant the same functional categorization. At the moment, none of these molecular markers serve as a prognostic indicator or as a guide to therapy, and we believe that it is appropriate to consider treating high-risk Merkel-cell carcinoma and small-cell lung cancer in a similar fashion. Most patients with clinical stage I disease (primary lesion, ≤2 cm in diameter; node-negative) do well with surgery or surgery plus radiation therapy and have a 5-year disease-specific survival rate of 81%; the rate is 68% for patients with clinical stage II disease (primary lesion, >2 cm; node-negative). 2 These rates are much lower than the 90% rate cited by Wong et al. Unfortunately, the majority of patients do not fare even this well, since the overall 5-year survival rates range from 30 to 64%. 3 In our opinion, this warrants more comprehensive therapy than surgery alone.
There are several issues we wished to put forward as points of consideration regarding the management of Merkel-cell carcinoma, recognizing that some may be controversial. First, there is a high degree of regional and systemic spread despite a seemingly limited primary cancer. Second, the sensitivity of gross regional disease to combined therapy suggests that surgery may not be necessary. Third, an aggressive regimen of combined treatment approaches can be delivered even in the setting of HIV infection and low CD4 cell levels. Fourth, radiation techniques can make a difference in acute and late morbidity. One point on which there is no disagreement is that we all base our opinions and treatment recommendations on a paucity of clinical information and formal clinical trials for a relatively rare but interesting disease. Paul M. Busse, M.D., Ph.D. John R. Clark, M.D.
